LPOXY Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapies for infectious disease prevention, signed an agreement to acquire selected assets from Xeno Biosciences Inc. The assets include regulatory filings, correspondence, and documentation from FDA and global regulatory interactions, as well as comprehensive CMC data. LPOXY will own data generated in Xeno’s Phase I and Ib clinical trials, which validates the safety of the Active Pharmaceutical Ingredient sha...